The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Open accessAbstract
It is known that bone mineral density (BMD) is low in men who are hypogonadal. However, the rate and sites of bone loss following testosterone deficiency are not known. The resulting hypogonadism after GnRH analog therapy for the treatment of prostate cancer allows us to examine bone loss and bone resorption immediately after testosterone withdrawal. Therefore, we examined the effects of GnRH analog treatment on bone loss and bone resorption in men with prostate cancer. BMD and serum and urine concentrations of markers of bone turnover were determined in men with prostate cancer and in age-matched controls. Measurements were taken before GnRH therapy and 6 and 12 months after instituting therapy. After 12 months of GnRH therapy, the BMD of the total hip and ultra distal radius decreased significantly (P < 0.001) in men with prostate cancer compared with the controls. The mean bone loss was 3.3% and 5.3%, respectively. The observed reduction in BMD in the spine (2.8%) and the femoral neck (2.3%) did not reach statistical significance. No significant bone loss was observed in the control subjects. The concentration of the urine marker of bone resorption, N-telopeptide, was significantly increased from baseline and from controls at both 6 and 12 months in patients treated with GnRH analog therapy compared with control subjects (P < 0.05). The concentration of a serum marker of bone formation, bone-specific alkaline phosphatase, was not significantly different from baseline or from controls at 6 and 12 months. Thus, the decreased total hip and ultra distal radius BMD and increased urinary N-telopeptide concentration after testosterone withdrawal demonstrate an increase in trabecular bone loss and enhanced bone resorption. These findings demonstrate a significant loss of bone in men with prostate cancer after receiving GnRH therapy and suggest that the total hip and radius are the preferred sites for monitoring bone loss in older men. In addition, markers of bone resorption may be helpful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Bone Density and Fracture Risk in Men
Dr. Melton, L. J., Atkinson, E. J., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.12.1915 · Cited by 684
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism
FINKELSTEIN, J. S., KLIBANSKI, A., NEER, R. M., GREENSPAN, S. L., ROSENTHAL, D. I., & CROWLEY, W. F. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3- · Cited by 408
RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER
Krongrad, A., Levis, S., & Roos, B. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64271-x · Cited by 339
Stevenson, J. C., Cust, M. P., Gangar, K. F., Hillard, T. C., Lees, B. L., Cust, M. P., Gangar, K. F., Hillard, T. C., & Whitehead, M. I. (1990) · The Lancet · doi:10.1016/0140-6736(90)91801-g · Cited by 278
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, R. E., & Delmas, P. D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1012 · Cited by 238
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens
Eriksson, S., Eriksson, A., Stege, R., & Carlstr�m, K. (1995) · Calcified Tissue International · doi:10.1007/bf00298427 · Cited by 191
Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists1
Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., & Greenspan, S. L. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7558 · Cited by 186
Goldray, D. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.2.288 · Cited by 174
Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001) · Urology · doi:10.1016/s0090-4295(00)00895-5 · Cited by 172
Androgen deprivation therapy for prostate cancer results in significant loss of bone density
Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J., & Cooney, K. A. (1999) · Urology · doi:10.1016/s0090-4295(99)00301-5 · Cited by 169
Percival, R. C., Urwin, G. H., Harris, S., Yates, A. J. P., Williams, J. L., Beneton, M. N. C., & Kanis, J. A. (1987) · PubMed · Cited by 124
Effect of menopause on femoral and vertebral bone loss
Pouillès, J. M., Trémollières, F., & Ribot, C. A. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101014 · Cited by 92
Osteoporosis due to androgen deprivation therapy in men with prostate cancer
Daniell, H. (2001) · Urology · doi:10.1016/s0090-4295(01)01251-1 · Cited by 69
Variability of vertebral and femoral postmenopausal bone loss: A longitudinal study
Pouillès, J. M., Trémollières, F., & Ribot, C. A. (1996) · Osteoporosis International · doi:10.1007/bf01623392 · Cited by 42
The Effects of Orchidectomy on Skeletal Metabolism in Metastatic Prostate Cancer
Clarke, N. W., McClure, J., & George, N. J. R. (1993) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365599309182280 · Cited by 36
Cited by
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01658 · Cited by 2,328
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0345 · Cited by 1,026
Metadata
- Authors
- Mittan, D.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-08-01
- Volume
- 87
- Issue
- 8
- Pages
- 3656-3661
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2172242835
- Cited by
- 278
- References
- 20
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.